Yes, leukemia can cause blood clots. About 12% of patients with acute leukemia develop at least one blood clot during their illness, and the risk comes from multiple directions: the cancer itself, the treatments used against it, and even the medical devices needed to deliver those treatments. The relationship between leukemia and clotting is more complex than with most other cancers, because leukemia can simultaneously increase the risk of both clotting and bleeding.
How Leukemia Triggers Clotting
Leukemia cells don’t just crowd out healthy blood cells. They actively interfere with the body’s clotting system in several ways. One of the most direct mechanisms involves a protein called tissue factor, which normally helps start the clotting process at wound sites. Certain leukemia cells produce large amounts of tissue factor and release it into the bloodstream on tiny cell fragments called microparticles. These microparticles act as vehicles, flooding the blood with clotting signals that don’t belong there.
Leukemia cells also drive inflammation that makes clotting worse. The cancer triggers overproduction of inflammatory molecules that damage blood vessel walls and ramp up multiple parts of the clotting system at once. These same molecules reduce the body’s ability to regulate clotting, creating a one-two punch: more clot formation and less natural clot prevention.
In cases where white blood cell counts climb extremely high, above 100,000 per microliter (normal is 4,000 to 11,000), a dangerous condition called leukostasis can develop. The sheer volume of abnormal white cells thickens the blood and can physically block small blood vessels, particularly in the lungs and brain. This is a medical emergency, though it can occasionally happen at lower cell counts depending on the type of leukemia.
Acute Promyelocytic Leukemia Carries the Highest Risk
Not all leukemias affect clotting equally. Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia, is notorious for causing severe clotting problems. Between 70% and 80% of APL patients develop a condition called disseminated intravascular coagulation (DIC) at diagnosis. DIC is a paradoxical state where the body forms tiny clots throughout the bloodstream while simultaneously using up so many clotting factors that dangerous bleeding occurs at the same time. In one study, more than half of APL patients had DIC-related bleeding at the time of diagnosis.
The culprit is the enormous amount of tissue factor that APL cells produce and release. Research has shown that when APL cells begin to mature during treatment, they release fewer of these clot-triggering microparticles, and the clotting abnormalities improve as therapy progresses.
Chronic Leukemia and Long-Term Clot Risk
Chronic leukemias carry a lower but sustained clot risk over time. A nationwide Danish study of over 3,600 patients with chronic lymphocytic leukemia (CLL) found a clot rate of about 8 per 1,000 patients per year. Within four years of diagnosis, roughly 2.3% of CLL patients had experienced a clot.
Several factors increased that risk. Patients who had a prior blood clot were five times more likely to develop another one. Those who developed a second cancer after their CLL diagnosis had nearly four times the risk. Certain biological markers associated with more aggressive CLL also raised clot risk, though not as dramatically as these other factors. Notably, active CLL treatment more than doubled the clot rate compared to periods of watchful waiting, with an incidence of 22 per 1,000 patient-years during treatment versus about 10 per 1,000 during observation.
Treatment Itself Can Cause Clots
Some of the drugs used to treat leukemia independently raise clot risk. One widely used chemotherapy agent in acute lymphoblastic leukemia (ALL) works by starving cancer cells of an amino acid they need. As a side effect, it disrupts the liver’s production of proteins on both sides of the clotting equation, but the proteins that prevent clotting drop more significantly than those that promote it. The result is a net shift toward clot formation, compounded by activation of the cells lining blood vessel walls.
Clot rates in ALL patients receiving this drug range from 1% to 36% depending on age and treatment intensity. Adults are hit hardest: 34% of adult patients in one large study developed clots, compared to 5% of children on the same treatment protocol. Clots typically appeared about three weeks into treatment, and the risk was highest during the initial intensive phase of chemotherapy. A large analysis of childhood ALL found the clot rate during induction therapy was more than double the rate in later treatment phases (4.8% versus 2.0%).
Central Line Clots
Leukemia patients almost always need a central venous catheter, a tube placed in a large vein for delivering chemotherapy and drawing blood. These lines are a significant clot source. In a study of 455 acute leukemia patients, half of all blood clots were directly associated with their central lines, affecting about 6% of patients. The other half were clots in typical locations like the deep veins of the legs or the lungs.
How Leukemia Compares to Other Cancers
Cancer in general raises clot risk, but leukemia doesn’t carry the highest rates. A large national study of over 1.2 million hospitalized cancer patients found that solid tumors caused more clots than blood cancers overall: 5.4% versus 4.1%. Among blood cancers specifically, lymphoma had the highest clot rates, followed by multiple myeloma, with leukemia behind both. Myeloid leukemia patients had a 3.9% clot rate during hospitalization, and lymphoid leukemia patients had a 3.4% rate.
These numbers can be misleading, though. They reflect hospitalized patients at a single point in time. The total lifetime clot burden in leukemia may be higher than snapshot studies suggest, especially given the long treatment courses and the compounding effects of catheters, chemotherapy, and the disease itself.
Symptoms to Watch For
Blood clots in leukemia patients show up in the same ways they do in anyone else, but they can also appear in unusual locations. Standard warning signs include swelling, warmth, or pain in one leg (suggesting a deep vein clot), sudden shortness of breath or chest pain (suggesting a clot in the lungs), and severe headache with vision changes (suggesting a clot in the brain’s veins).
Leukemia patients may also develop clots in less common sites like the veins of the abdomen, which cause persistent abdominal pain, bloating, and sometimes fever. These atypical clots can occasionally be the first sign of an undiagnosed blood cancer. Because leukemia patients often have low platelet counts that cause easy bruising and bleeding, the simultaneous presence of clotting symptoms can be confusing. Swelling in one arm, particularly on the side where a central line is placed, is another common presentation.
The Treatment Paradox
Managing blood clots in leukemia patients is uniquely challenging because the same disease that causes clots also causes bleeding. Leukemia often drives platelet counts dangerously low, and conditions like DIC consume clotting factors faster than the body can replace them. Standard blood thinners, the go-to treatment for clots in other patients, become risky when platelets are depleted.
Clinical guidelines generally require platelet counts above 50,000 per microliter before blood thinners can be safely given. Many leukemia patients fall below that threshold, particularly during intensive chemotherapy. This means treatment teams often have to balance platelet transfusions with anticoagulation, adjusting both in real time as counts fluctuate. For patients with APL-related DIC, treating the leukemia itself is the most effective way to resolve the clotting disorder, since the clotting abnormalities improve as the cancer responds to therapy.